drugset / Trial / NCT02546388
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
Timeline
- Start
- 2015-10
- Primary completion
- 2018-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-DOTATATE | Diagnostic / imaging agent | — | — |
| Subject | Indium-111 Pentreotide | Diagnostic / imaging agent | — | — |